Live Terminal
Telegram

After 156% surge in a day, this American firm stock rises another 5%. What's driving the biotech share rally?

Share on WhatsApp Telegram
⚡ Instant Key Takeaways (TL;DR)
🎯
Core Development: After 156% surge in a day, this American firm stock rises another 5%. What's driving the biotech share rally?
📊
Market & Financial Impact: Sellas shares climbed after its Phase 3 trial of GPS showed a significant survival benefit for patients with acute myeloid leukemia and no new safety concerns. The company plans to discuss an accelerated filing strategy with the FDA and aims to submit an application in 2027.
💡
Actionable Insight: 🟢 Bullish Trigger: Positive business expansion or earnings beat may attract institutional and retail buying.

Shares of US-based biotechnology company Sellas Life Sciences extended their spectacular rally on Wednesday, November 18, rising another 5% after soaring nearly 156% in the previous session.

The stock has come under investors' radar following a major breakthrough in a late-stage clinical trial of its experimental cancer vaccine, which demonstrated a significant improvement in survival outcomes among patients with an aggressive form of blood cancer.

The sharp rally came after the company announced positive results from its pivotal Phase 3 REGAL trial evaluating galinpepimut-S (GPS), an investigational immunotherapeutic cancer vaccine designed to treat acute myeloid leukaemia (AML).

The results marked a significant milestone for the company, with the trial meeting its primary endpoint of overall survival. Sellas said the treatment reduced the risk of death by 41% compared with the best available treatment, with a hazard ratio of 0.59 and a statistically significant p-value of 0.035, as per the company's press release.

The company said that the 126-patient study showed that patients receiving GPS achieved median overall survival of 24 months, compared with 14.7 months among those receiving the best available treatment.

📰
Official Publisher Attribution: This report is aggregated from LiveMint. ZeroLive provides live aggregation, automated sentiment synthesis, and exchange disclosure monitoring for retail market participants.
Read Original Full Coverage on LiveMint ↗
⚡
Get Breaking Stock Alerts & Q-Results on Telegram
Real-time 1200x675 image cards and financial filings delivered instantly.
Join @Zerolive_news ↗
Link copied to clipboard! ✅